Table 1.
Demographics and levels of wild type and variants of concern B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), and B.1.617.2 (Delta) RBD-specific IgG and neutralizing antibodies 1-2 weeks post vaccination in the different study groups. Continuous variables are presented with median and interquartile range while proportions are converted to proportions that sum to 100% in the vertical axis. BNT; BNT162b2, ChAd; ChAdOx1 nCoV-19 AU; arbitrary units. kAU; kilo arbitrary units.
| BNT x 2 | ChAd x 1 | ||
|---|---|---|---|
| SARS-CoV-2 naïve N=65 |
Inf. >11 m. prior vx N=45 |
Inf. <11 m. prior vx N=37 |
|
| Age | 52 (42 - 58) | 48 (41 - 59) | 47 (40 - 52) |
| Female | 57 (88%) | 37 (82%) | 35 (95%) |
| RBD IgG (kAU/ml) | |||
| Wild type | 49 (37 - 82) | 94 (51 - 155) | 56 (33 - 128) |
| Alpha (B.1.1.7) | 49 (35 - 81) | 101 (54 - 157) | 58 (33 - 124) |
| Beta (B.1.351) | 23 (16 - 36) | 49 (26 - 83) | 24 (12 - 67) |
| Gamma (P.1) | 37 (25 - 56) | 68 (41 - 117) | 36 (19 - 89) |
| Delta (B.1.617.2) | 52 (36 - 78) | 95 (51 - 141) | 55 (29 - 111) |
| RBD NAb (AU/ml) | |||
| Wild type | 46 (38 - 55) | 55 (44 - 70) | 53 (38 - 65) |
| Alpha (B.1.1.7) | 41 (31 - 50) | 52 (38 - 70) | 45 (34 - 64) |
| Beta (B.1.351) | 36 (21 - 47) | 41 (17 - 63) | 37 (21 - 58) |
| Gamma (P.1) | 32 (24 - 35) | 38 (25 - 56) | 32 (25 - 47) |
| Delta (B.1.617.2) | 41 (34 - 49) | 50 (36 - 63) | 43 (35 - 52) |